Latigo Biotherapeutics

LTGONasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$1.078 B

$16.26 -2.23%

Close of 7 Oct 2026

As of 7 Oct 2026, Latigo Biotherapeutics (LTGO) has a market capitalization of $1.08B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

66,299,347

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#144Bicara TherapeuticsBCAX$1.10B
#145Opko HealthOPK$1.09B
#146Latigo BiotherapeuticsLTGO$1.08B
#147Janux TherapeuticsJANX$1.03B
#148Aktis OncologyAKTS$993.4M

Insiders buying

All insider buying →

2 open-market purchases by officers and directors of Latigo Biotherapeutics, worth $5.04M. Grants and option exercises are excluded.

Foresite Capital Fund V, L.P., Foresite Capital Fund VI LP, Foresite Capital Management V, LLC, Foresite Capital Management VI LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC$2.52M
140,000 shares at $18.00 on 10 Aug 2026 · filed 10 Aug 2026
James B. Tananbaum$2.52M
140,000 shares at $18.00 on 10 Aug 2026 · filed 10 Aug 2026

What if Latigo Biotherapeutics were worth as much as…

Open the what-if tool →

Gold $28.8T

$434,234.06

Per share 26,706× higher

Bitcoin $1.67T

$25,192.52

Per share 1,549× higher

Nvidia $5.77T

$86,964.42

Per share 5,348× higher

Or at a round number

$2.00B $5.00B $10.0B $20.0B

Where these numbers come from

Share counts and financials for Latigo Biotherapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 8 Oct 2026. Read the methodology.